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Background: This study evaluated the anti-inflammatory effects of Resolvin-D1 (RV-D1) and its mechanism of action
in human corneal epithelial (HCE) cells.
Methods: HCE cells were incubated with different concentrations of RV-D1 for different time periods. Oleic acid
(OA) and Dexamethasone (DM) served as negative and positive controls, respectively. Cells were stimulated with
polyriboinosinic:polyribocytidylic acids (poly I:C). The protein contents and mRNA expression levels of Tumor necrosis
factor-α (TNF-α), Interleukin (IL)-6, IL-1β and IL-8 were evaluated with multiplex fluorescent bead immunoassay (FBI) and
real time-PCR, respectively. In addition, the expression of inhibitory factor-κBα (I-κBα) was evaluated with real time-PCR.
Results: The protein level of pro-inflammatory cytokines TNF-α, IL-6, IL-1β and IL-8 significantly increased after
stimulation with Poly I:C. RV-D1 treatment at concentration of 1 μM decreased the protein level of TNF-α to 20.76 ± 9.3%
(P < 0.05), IL-6 to 43.54 ± 14.16% (P < 0.001), IL-1β to 46.73 ± 15.93% (P > 0.05) and IL-8 to 51.15 ± 13.01% (P < 0.05)
compared with cells stimulated with poly I:C alone. Similarly, the mRNA levels of TNF-α, IL-6, IL-1β and IL-8 were
significantly reduced after treatment with RV-D1. A highly significant dose response curve was demonstrated for
RV-D1 treated HCE cells for TNF-α and IL-1β.
DM treatment decreased the protein content for all of the pro-inflammatory cytokines, similar results were demonstrated
at the mRNA level. The anti-inflammatory effects of RV-D1 were similar to those of DM for TNF-α, IL-6 and IL-8.
Conclusions: RV-D1 may serve as a potent anti-inflammatory agent in ocular surface inflammation, as evaluated in
cultured HCE cells. The anti-inflammatory effects of RV-D1 were comparable to those of DM, and were mediated through
nuclear factor kappa B (NF-κB) signal transduction.
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Chronic inflammation of the ocular surface is a common
characteristic of many common diseases such as the dry
eye syndrome (DES), allergic conjunctivitis and contact
lens intolerance [1-3]. The inflammatory process can cause
significant damage to the corneal and conjunctival epithelia,
with subsequent visual loss [4].
Current topical treatment options for ocular surface
inflammation include mainly corticosteroids, non-steroidal
anti-inflammatory agents and Cyclosporine A. Topical
corticosteroids have shown efficacy in treating DES with a* Correspondence: dr.avi.solomon@gmail.com
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reproduction in any medium, provided the orrapid onset of action [5], but are limited because of their
potential side effect, such as posterior sub-capsular
cataract and increased intraocular pressure [6]. Topical
non-steroidal anti-inflammatory agents have limited
anti-inflammatory activity and may impede wound healing
[7]. Cyclosporin A takes a few weeks before achieving sig-
nificant results, its efficacy is controversial, and it is indi-
cated for mild to moderate inflammatory conditions [8].
Recently, there has been a large amount of interest in
using poly-unsaturated fatty acids (PUFAs) as a treatment
for ocular surface inflammatory disease [9]. A recent study
has indicated that dietary or oral supplementation of PUFA
may improve symptoms of DES and contact lens intoler-
ance [10]. Dietary supplementation of Eicosapentaenoic
acid (EPA) and Docosahexaenoic acid (DHA) reduced
the prostaglandin levels in the dry eye rat model, andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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portant symptom associated with DES [11]. A study by
Rashid et al. using a dry eye mouse model has shown
that topical administration of omega-3 fatty acids de-
creased dry eye signs and inflammatory changes at both
cellular and molecular levels [12].
We have recently shown that alpha-linolenic acid
(ALA), an omega-3 poly-unsaturated fatty acid, has po-
tent anti-inflammatory effects on stimulated human
corneal epithelial cells. Both protein and mRNA levels
of several pro-inflammatory cytokines were dramatically
decreased following treatment with ALA [13]. The re-
sults of that study have paved the way for further search
of PUFAs bioactive derivatives, which may have a stronger
anti-inflammatory effect.
Recently studies demonstrated that several of the
bioactive derivatives of PUFAs possess potent anti-
inflammatory effects, and can also promote the reso-
lution of acute or chronic inflammatory processes.
These studies have demonstrated a tightly controlled
and programmed mechanism involving the resolution
of inflammatory processes [14]. In order for an inflam-
matory process to be extinguished, the production of
pro-inflammatory mediators should decrease, while the
production of anti-inflammatory pro-resolution mediators
should increase. In the PUFAs family, four new groups
of such pro-resolution mediators have been identified:
Lipoxins (LXs), Protectins (PTs), Maresins (MaR) and
Resolvins (RVs). RVs are non-classical Eicosanoids, which
are endogenous, potent, local acting molecules [4,14].
RVs can be formed by metabolizing EPA and DHA.
Two main classes of resolvins have been identified. The
E-series RVs are formed when EPA is metabolized first
by cyclooxygenase-2 (COX2) or the cytochrome-P450
pathway in vascular endothelial cells, and then by neu-
trophil 5-lipooxygenase (5-LOX) [15]. On the other
hand, the D-series RVs can be formed by metabolizing
DHA first by 15-lipooxygenase (15-LOX) and then by
5-LOX. Another pathway to form the D-series RVs is
based on the presence of Aspirin, which triggers COX-2
to metabolize DHA, which in turn is metabolized by
5-LOX to create RV-D [15].
Resolvins were shown to be extremely potent anti-
inflammatory agents. Nano-molar doses of RV-E1 promote
the resolution of inflammatory allergic airway responses by
directly suppressing the production of IL-23 and IL-6, and
inducing dramatic reduction of dermal inflammation,
peritonitis, dendritic cell migration and inflammatory
cytokine production [16,17]. RVs also limit polymorphic
nuclear leukocytes infiltration and promote macrophages
activity at the inflammation site, without causing systemic
immunosuppressive activity [18].
Bazan et al’s study showed that after exposing mice to
desiccating conditions, RV-E1 increased tear productionby 60% compared to control [19]. Another study held by
Pflugfelder et al. in a murine model of dry eye has
shown that RV-E1 improves the outcome measures of
corneal staining and goblet cell density, implying the
potential of RVs as a future treatment for DES [20].
Resolvin D1 (RV-D1) is one of the mediators of the
RV family, with potential anti-inflammatory effects. As of
today, the direct local anti-inflammatory pro-resolution
effects of RV-D1 on ocular surface cells have not been
studied. In this study we investigated the direct local anti-
inflammatory effects of RV-D1 on HCE cells in-vitro,
comparing these effects with those of corticosteroids,
in order to evaluate its efficacy as a possible anti-
inflammatory agent for the treatment of ocular surface
inflammatory disorders.Methods
The Hadassah Medical Center Institutional Review Board
(IRB) approval was obtained for this study (IRB protocol
number and version: EFA-EFE-IV-01), and all of the
study procedures were carried out in accordance with
the IRB guidelines. This study followed the tenets of
the Declaration of Helsinki.Culture of Human Corneal Epithelial (HCE) cells
HCE cells were cultured from human corneoscleral rim
explants, taken from several different human donors,
provided by the Department of Ophthalmology at the
Hadassah Medical Center, using a previously described
method [21]. In brief, HCE cells were cultured in supple-
mented hormonal epithelial medium (SHEM) [22]. HCE
cells were incubated at 37°C under 95% humidity and
5% CO2. The culture medium was replaced every other
day. Cultures were kept for 10 to 14 days until a density
of 90% confluence was observed. At this time, cells were
passaged and seeded onto 6-well plates at a density of
2.0×105 cells/well. Cells were observed by phase-contrast
microscopy to ensure uniformity of morphology. The
purity of HCE cultures was confirmed by staining for
cytokeratin-19 with the indirect immune-peroxidase pro-
cedure with monoclonal antibody to human cytokeratin-19
(Abcam, Cambridge, UK). Second generation cells were
used in all experiments.Drug preparation
Stock solution of RV-D1 was obtained by Cayman
Chemical (Ann Arbor, Michigan, USA). Drug prepar-
ation and aliquots was performed at a nitrogen chamber,
filtered through 0.2-μm-pore-size filters, divided to ali-
quots and sealed under nitrogen in opaque Eppendorf
tubes. RV-D1 was stored at -80°C for no longer than
14 days before treatments.
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HCE cells were seeded into 6-wells plates for 24–48 hours
before the experiment, at a density of 1.2 × 105 cells/well
in 2.0 ml of medium. Culture medium was exchanged
every other day, and cultures were maintained until sub-
confluence. RV-D1 was conjugated with Bovine serum
albumin (BSA; Fraction V, Mercury, Israel) at a maximal
concentration of 0.1% according to a previous study [23].
HCE cells were pre-incubated for two hours with RV-D1
before the inflammatory stimulus, based on a previous
protocol [24]. In order to avoid oxidative effects, the fatty
acids were defrosted once and were not reused again.
After incubation of the HCE cells with the RV-D1 and
the controls, the cells were not washed out and were
treated with Poly I:C at a dose of 25 μg/ml as previously
described [25]. In addition, in order to examine the
RV-D1 effect on baseline cytokines level, HCE cells
were incubated without any stimulus, and then with
and without RV-D1 treatments.
For maximal induction of IL-6 and IL-8, the stimulus
exposure time lasted 4 hours for protein contents and
3 hours for mRNA expression levels, after the cells were
pre-incubated for 2 hours with RV-D1 and the controls
(hence, the total incubation time was 6 and 5 hours for
protein and mRNA, respectively). For TNF-α and IL-1β,
the stimulus lasted 15 hours for protein contents, and
12 hours for mRNA expression levels, after cells were
pre-incubated for 2 hours with the RV-D1 and the con-
trols (therefore, the total incubation time was 17 and
14 hours for protein and mRNA, respectively). In
addition, RV-D1 was incubated at doses of 1 μM, 0.1 μM
and 0.01 μM for dose–response curves evaluation.
Dexamethasone (DM) served as a positive control at a
concentration of 10−5 M [26], while Oleic acid (OA)
served as a negative control, at a concentration of 200 μM,
due to its lack of effect on eicosanoid biosynthesis [27]. At
the end of each treatment, the cells were examined with
FITC-Annexin V/PI. Culture supernatants were collected,
aliquoted and stored at -80°C for further measurements of
the protein contents of the inflammatory mediators. Total
RNA was extracted from the cells and stored at -80°C
until thawed for cDNA-PCR.
Two hours before the experiment, the medium was
replaced to 2 ml of serum-free medium (SFM) in each
well. All the study experiments were performed in HCE
cells that were cultured from human corneoscleral rim
explants, taken from four different human donors.
HCE cells viability
The apoptosis assay was performed as described previ-
ously [28]. In brief, at the end of each treatment HCE
cells viability was assessed by flow cytometry using an
Annexin V apoptosis detection kit (MBL, Nagoya, Japan).
One μg/ml of Annexin V-FITC and 1 μg/ml of Propidiumiodide (PI) were added to the cell suspension, and the
mixture was incubated in the dark for 5 min at room
temperature. Without washing, the cells were placed in
500 μl of Annexin V binding buffer and kept on ice, and
within 5 min were evaluated using a Coulter FC-500 flow
cytometer (Beckman-Coulter, Fullerton, CA, USA). Flow
cytometry data were analyzed using CXP Analysis 2.0
software (Beckman-Coulter, Miami, FL, USA).
Protein contents of inflammatory cytokines - multiplex
Fluorescent Bead Immunoassay (FBI)
The cytokines protein concentration levels were mea-
sured using a multiplex fluorescent bead immunoassay
(Cytometric bead array, CBA, Human Inflammatory
Cytokines Kit, BD Biosciences, San Jose, CA, USA).
This kit allows the simultaneous measurement of protein
levels of Interleukin (IL)-1β (IL-1β), IL-6, IL-8, IL-10,
Tumor Necrosis Factor Alpha (TNF-α), and IL-12 (p70)
in a single sample. The test was performed and analyzed
according to the manufacturer’s instructions and was
performed as described previously [29]. Briefly, 50 μl of
six premixed capture beads populations (coated with
capturing antibodies specific for different cytokines or
chemokines) were mixed with 50 μl of the provided
standards. Eight point standard curves ranging from 20
to 5000 pg/ml were obtained by serial dilutions of the
reconstituted lyophilized standards. Fifty microliters of
capture beads populations were also mixed with culture
supernatant samples, allowing for the different cyto-
kines in the samples to be captured by their analogous
beads. Afterwards, the cytokines capture beads were
mixed with 50 μl of phycoerythrin-conjugated detection
antibodies to form sandwich complexes. These sandwich
complexes were successively incubated in the dark for
3 hours at room temperature. After incubation the mix-
ture was washed, centrifuged (at 200× g for 5 min) and
the pellet was resuspended in 300 μl of wash buffer. The
BD LSRII flow cytometer (BD Biosciences, San Diego, CA,
USA) was calibrated with setup beads and 1,800 events
were acquired for each sample. Results were generated in
graphical format and analyzed with FCAP array software
v1.0.1 (BD Biosciences, San Diego, CA, USA).
RNA isolation
Total RNA was extracted from the HCE cell samples
with RNAqueous Kit (Ambion, Austin, TX, USA) follow-
ing the manufacturer’s instructions. Quantification of total
RNA was performed in a NanoDrop spectrophotometer
(ND-1000; Nano-Drop Technologies, Wilmington, DE,
USA). RNAs were stored at −80°C until further utilization.
cDNA synthesis
cDNA was synthesized from purified and concentrated
0.5 μg RNA from each sample using a High Capacity
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ABI, USA). A 20 μl total reaction volume was made with
10 μl RNA, 2 μl 10× RT buffer, 0.8 μl dNTP Mix
(100 mM), 2.0 μl 10× RT random hexamer primers,
1.0 μl MultiScribe™ reverse transcriptase, 1 μl RNase in-
hibitor and 3.2 μl nuclease-free water. Synthesis was
carried out in an ABI 7900 Thermo cycler (Applied
Biosystems, Foster City, CA, USA) and reaction condi-
tions were 25°C for 10 minutes, 37°C for 120 minutes, and
85°C for 5 minutes. cDNA samples were stored at −20°C.Real-time polymerase chain reaction
Real-time polymerase chain reaction (PCR) was per-
formed using TaqMan® Gene Expression Assays (Applied
Biosystems, Foster City, CA, USA) in the ABI Prism
7900HT Sequence Detection System (Applied Biosystems,
Foster City, CA, USA) as described previously [30]. Nega-
tive controls were included to evaluate DNA contamin-
ation of isolated RNA and reagents.
Real-time polymerase chain reaction assays for the
selected cytokines were: TNF-α, IL-1β, IL-6 and IL-8
(Applied Biosystems, Foster City, CA, USA) and I-κBα
(Applied Biosystems, Foster City, CA, USA). An amount
of 1 μL cDNA was loaded in each total volume of 20 ml of
reaction mixture and assays were performed in triplicates.
The fold changes of the gene expression in the sam-
ples were normalized to the endogenous gene hypo-
xanthine phosphoribosyltransferase 1 (HPRT1; Applied
Biosystems, Foster City, CA, USA). Quantitative ana-
lysis was performed using the comparative (ΔΔCT)
method, in which CT value is defined as the cycle num-
ber in which the detected fluorescence exceeds the
threshold value, ΔCT is the difference between CT of a
target gene and the endogenous control, and ΔΔCT is
the difference between ΔCT of the analyzed sample
and the calibrator (control sample) [30]. The results
were analyzed by DataAssist™ Software Version 2.0
(Applied Biosystems, Foster City, CA, USA).Statistical analysis
All tests were carried out on four independent cell cul-
tures, derived from four different cornea donors, and
performed in triplicates for each of the treatments. The
levels of the cytokines protein contents and mRNA
expression were calculated as a ratio relative to medium.
Statistical analysis and multiple comparisons were per-
formed by one-way ANOVA using the InStat software
version 3.0 (GraphPad Software Inc, San Diego, CA, USA).
The median effective concentration (EC 50) of RV-D1
was calculated with sigmoid Emax model. The pharma-
cokinetic modeling was performed using WinNonlin® 6.2
software (Pharsight Corporation, USA).Results
Cell viability following RV-D1 treatments
HCE cells were cultured with RV-D1 at several concen-
trations and periods of time as described above. Cell via-
bility following RV-D1 and the control groups were
examined with Annexin V-FITC PI assay (MBL, Nagoya,
Japan) at the end of each treatment. The viability of the
HCE cells at the end of the treatments was 95 ± 2% in
comparison to the medium only, which served as a
negative control (data not shown). There were no sig-
nificant differences in cell viability between the treat-
ment groups (RV-D1, OA, DM) and the negative control
(medium only). In addition, there were no significant
differences in cell viability among each concentration of
the RV-D1 treatments (1 μM, 0.1 μM, 0.01 μM) and the
negative control.
Stimulation of HCE cells (multiplex FBI)
HCE cells incubated with poly I:C expressed up to 4-fold
higher levels of IL-6 (P < 0.05), 7-fold higher IL-1β
(P < 0.01), 13-fold higher TNF-α (P < 0.01), and 3-fold
higher IL-8 (P < 0.05) in HCE cells compared with incuba-
tion in medium only (Figures 1A-D).
The RV-D1 effect on the baseline cytokines level
In order to examine the effect of RV-D1 on the back-
ground secretion level of the cytokines, RV-D1was incu-
bated in un-stimulated cells (Figures 1A–D).
There were insignificant differences between the de-
crease of the cytokines (TNF-α, IL-6, IL-1β and IL-8)
level after treatments with and without RV-D1 treat-
ments in unstimulated cells.
RV-D1 inhibit poly I:C-induced cytokines protein
production (multiplex FBI)
RV-D1 treatment with concentration of 1 μM signifi-
cantly decreased TNF-α protein secretion to 20.76 ± 9.3%
(P < 0.05), IL-6 to 43.54 ± 14.16% (P < 0.001), IL-1β to
46.73 ± 15.93% (P > 0.05) and IL-8 to 51.15 ± 13.01%
(P < 0.05), compared with poly I:C stimulus alone
(Figures 1A–D). OA, which served as a negative control,
did not cause a significant decrease in cytokines protein
contents. These anti-inflammatory effects of RV-D1 were
comparable with those of DM (excluding IL-1β), which
decreased TNF-α protein secretion to 28.17 ± 11.90%
(P < 0.05), IL-6 to 39.27 ± 6.96% (P < 0.001), IL-1β to
41.92 ± 15.0% (P < 0.05), and IL-8 to 37.63 ± 13.21%
(P < 0.001), compared with incubation of HCE cells
with poly I:C only. There was no significant difference be-
tween the decrease in cytokines level after treatments with
either DM or RV-D1 in HCE cells after stimulation with
poly I:C (excluding IL-1β), suggesting again similar anti-







































































































Figure 1 RV-D1’s Effects on Poly I:C-Induced pro-inflammatory cytokines protein secretion in HCE cells (A-D). For TNF-α and IL-1β detection
the HCE cells were stimulated in SFM with Poly I:C (25 μg/cc) for 15 hours and cells pre-incubated for 2 hours with RV-D1 at 1 μM (A, C). For IL-6
and IL-8 detection the HCE cells were stimulated with Poly I:C for 4 hours and cells pre-incubated for 2 hours with RV-D1 at 1 μM (B, D). Data
shown is the ratio to stimulus with poly I:C only (mean ± SD) from four independent experiments (n = 4). Asterisks indicate a significant difference
(P < 0.05) between groups compared to poly I:C only.
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in poly I:C–stimulated HCE cells (examined by
multiplex FBI)
HCE cells were further incubated with RV-D1 at con-
centrations of 1 μM, 0.1 μM and 0.01 μM respectively.
For maximal induction of IL-6 and IL-8, the stimulus
exposure time lasted 4 hours, and for TNF-α and IL-1β
the stimulus lasted 15 hours.
Significant dose response curves were demonstrated for
RV-D1 treatment doses for TNF-α and IL-1β (Figure 2A).
The median effective concentration (EC 50) of RV-D1
values were 460.91 ± 280 nM for IL-1β and 4.81 ± 1.33
nM for TNF-α and the dose response correlation coeffi-
cients were >0.942 (p < 0.05). In contrast, there were insig-
nificant differences in EC 50 of values for IL-6 and IL-8
(Figure 2B).Inhibition of Poly I:C-induced gene expression of
cytokines examined by real-time PCR
The mRNA expression levels of IL-6, IL-1β, TNF-α, and
IL-8 were significantly increased in HCE cells upon
stimulation with poly I:C (Figures 3A–D), compared
with un-stimulated cells. RV-D1 treatment in HCE cells
after stimulation with poly I:C (Figures 3A–D) elicited a
significant reduction of TNF-α mRNA levels to 16.81 ±
17.9% (p < 0.01), IL-6 to 30.67 ± 14.84% (p < 0.05), IL-1β
to 37.26 ± 3.42% (p < 0.05), and IL-8 to 27.55 ± 4.95%
(p < 0.01), compared with incubation of the cells with
poly I:C only. DM treatment decreased TNF-α mRNA ex-
pression levels to 11.03 ± 8.5% (p < 0.01), IL-6 to 14.14 ±
2.42% (p < 0.01), IL-1β to 25.5 ± 5.26% (p < 0.01), and IL-8
to 15.22 ± 8.99% (p < 0.01), compared with incubation of






























































































Figure 2 A dose–response reduction of TNF-α, IL-1β (A) IL-6, IL-8 (B) by RV-D1 in Poly I:C (25 μg/cc) stimulated in HCE cells. For TNF-α
and IL-1β detection the HCE cells were incubated in SFM with RV-D1 for 15 hours and cells pre-incubated for 2 hours with RV-D1’s at 1 μM,
0.1 μM and 0.01 μM (A). For IL-6 and IL-8 detection the HCE cells were incubated in SFM with Poly I:C for 4 hours and cells pre-incubated for
2 hours with RV-D1at 1 μM, 0.1 μM, and 0.01 μM (B). For IL-1β and TNF-α the dose response correlation coefficients were >0.942 (p < 0.05).
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in the levels of all the cytokines mRNA expression levels
between the DMs treatment and RV-D1s treatment.Effects of RV-D1 on inhibitory factor-IκBα (I-κBα) mRNA
expression levels
RV-D1 treatment in HCE cells after stimulation with
poly I:C elicited a significant reduction of IκBa mRNA
expression levels to 30.03 ± 20.51% (p < 0.05) (Figure 4),
while DM treatment decreased IκBa mRNA expressionlevels to 24.6 ± 10.64% (p < 0.01) after stimulation with
Poly I:C.
Discussion
This study indicates a highly potent anti-inflammatory
effect of RV-D1 on HCE cells in-vitro. RV-D1 reduced
significantly the Poly I:C inflammatory reaction and
dramatically reduced the production of the pro-
inflammatory cytokines TNF-α, IL-6, IL-1β and IL-8
in cultured HCE cells. The reduction effect was dem-
































































































Figure 3 RV-D1’s effects on poly I:C-induced cytokines mRNA expression levels in HCE cells, examined by real-time PCR (A–D). mRNA
expression levels are presented on a logarithmic scale. For TNF-α and IL-1β detection the HCE cells were incubated in SFM with RV-D1 for 12 hours
and cells pre-incubated for 2 hours with RV-D1 at 1 μM (A, C). For IL-6 and IL-8 detection the HCE cells were incubated in SFM with Poly I:C for 3 hours
and cells pre-incubated for 2 hours with RV-D1’s at 1 μM (B, D). Data is expressed as percentage (mean ± SD) of the expression found after poly I:C
stimulation, which was normalized to 1.0, and derived from four independent experiments (n = 4). Asterisks indicate a significant difference (P < 0.05)
between groups compared to poly I:C only.
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nificant dose-dependent reduction was demonstrated
by RV-D1 for TNF-α and IL-1β.
RV-D1 demonstrated inhibitory effects on the protein
production of the inflammatory mediators, which werecomparable to those of DM. Furthermore, the HCE cells
stimulated by Poly I:C and treated with RV-D1 demon-
strated a decrease in I-κBα mRNA expression, suggesting
that the anti-inflammatory effects of RV-D1 involve regula-
























Figure 4 RV-D1’s effects on Poly I:C-induced IκBα mRNA
expression levels in HCE cells. HCE cells were stimulated in SFM
with Poly I:C (25 μg/cc) for 12 hours after cells pre-incubated for 2 hours
with RV-D1’s 1 μM. mRNA expression levels of IκBα were examined
by real time PCR. The mRNA expression levels are presented in a
logarithmic scale, data are expressed as percentage (mean ± SD) of the
Poly I:C stimulus which was normalized to 1.0 from three independent
experiments (n = 3). Asterisks indicate a significant difference (P < 0.05)
between groups compared to poly I:C only.
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pro-inflammatory mediators including adhesion mole-
cules, chemokines and cytokines such as IL-1β, IL-6,
IL-8, TNF-α in the tears and the ocular surface epithelia
of DES patients and animal models [1,31]. Topical use
of corticosteroids decreases the inflammatory response
with a very high efficiency and a rapid onset of action
[5]. Nevertheless, the disadvantages lay mainly in their
significant adverse effects on long term use, as they may
cause posterior sub-capsular cataract or increase the
intraocular pressure [6,31]. Since most of the ocular
conditions that involve inflammatory process, such as
Sjögren’s syndrome and DES, are characterized by a
chronic course, corticosteroids seem to have a limited
role in their management. Another anti-inflammatory
agent that has been tested topically is Cyclosporin A.
The efficiency of this drug is controversial among different
clinical researchers and studies. Apparently, Cyclosporin
A has some efficiency, but it requires several months to
obtain its maximal therapeutic anti-inflammatory effects,
which can fit to the chronic course of these conditions
[32]. Considering the significant disadvantages of topical
corticosteroids treatment on one hand, and the limited
efficiency of topical Cyclosporin A treatment on the
other hand, there is still a necessity for an efficient yetsafe agent for treating topically the chronic inflamma-
tory diseases of the ocular surface.
During the recent years, a significant progress has
been made on understanding the inflammatory process.
It is now believed that an inflammatory process has 3
phases: onset, peak and resolution [14]. The onset is char-
acterized by exceeded production of pro-inflammatory
mediators, whereas during the peak there is a switch to
the production of anti-inflammatory pro-resolution medi-
ators, until their predominance divert the process towards
resolution. Hence, an inflammatory process also triggers
its own regulation, since as the production of anti-
inflammatory pro-resolution mediators intensifies, the
production of pro-inflammatory mediators decreases,
and the inflammatory process is alleviated [14]. Studies
which have evaluated the resolution phase have led to
the understanding that anti-inflammatory pro-resolution
agents can relieve the signs and symptoms of DES, and
even lead to a complete resolution.
Studies which were done on the resolution phase had
shown that the PUFAs bioactive derivatives have potent
anti-inflammatory effects, qualities which give them a role
at regulating acute or chronic inflammatory processes
[14]. Rashid et al’s study has shown that the topical ad-
ministration of omega-3 fatty acid in DES mouse model
decreased the number of CD11b + cells and the levels of
pro-inflammatory cytokines such as IL-1α and TNF-α in
the ocular surface.7 Recently, a study we have conducted
had shown that administration of Alpha linolenic acid
(ALA) to HCE cells stimulated by Lipopolysaccharide
(LPS) or polyriboinosinic:polyribocytidylic acids (poly I:C)
in-vitro significantly reduced the protein and mRNA levels
of several pro-inflammatory cytokines [13].
Realizing the potential PUFAs have, have led to exten-
sive research of these materials, resulting in the identifi-
cation of four new groups of molecules, which are
metabolites of PUFAs: LXs (synthesized from arachi-
donic acid), RVs and PTs (derived from omega-3 fatty
acids-EPA and DHA), and MaR (derived from DHA)
[4,14]. Nowadays, tremendous efforts are invested in
order to evaluate the anti-inflammatory pro-resolution
impact of these bioactive derivatives on the inflamma-
tory response.
RVs, as a family of bioactive PUFA derivates, have a
vast range of actions, extracellular as well as intracellu-
lar. Their mechanism of action is not fully understood,
but they seem to have effects on immune cells as well as
non-immune ones, which can imply they have several
biologic purposes. Studies have shown RVs decrease pro-
duction of pro-inflammatory mediators as well as have
immune-modulatory effects, which can imply on their
anti-inflammatory pro-resolution activities [15-17].
RV-E1 has been studied for several years and may
imply the potential anti-inflammatory effects of RV-D1,
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administration of RV-E1 reduces neutrophils infiltration
in murine models [33], can inhibit LTB4-stimulated
transmigration in-vitro, and activate PMN phagocytosis
in order to clean the tissue and reduce production of some
pro-inflammatory cytokines such as IL-6 and INF-γ [15].
Because neutrophil infiltration is an early stage of any in-
flammatory process, and PMN phagocytosis is an early
stage of resulotion [14,15], the fact that RVs reduce neu-
trophil infiltration by at least 4 different ways [15] and
activate PMN phagocytosis, indicates they have a strong
active pro-resolution effect.
A study of allergic airway inflammation indicates RV-E1
treatment reduces neutrophil and eosinophil infiltration,
decreases Th2 number and decreases mucus production
of the epithelium [34]. The result of the treatment was
reduced lung damage and less bronchoconstriction [35].
Studies of colitis in a mice model have demonstrated that
treating with RV-E1 reduced leukocytes amount, reduced
production and secretion of IL-12, TNF-α and other pro-
inflammatory cytokines [36] and decreased filled goblet
cells [35]. The results were lower mortality rate, reduced
weight loss and reduced colon shortening [36].
Recently, studies have investigated the effect of RV-E1
on different ocular pathologies. A study of corneal in-
flammation and neovascularization in a suture-induced
model has demonstrated RV-E1 can reduce inflamma-
tion and neovascularization by dramatically minimizing
leukocyte infiltration and reducing both TNF-α and
VEGF-A production [37]. Furthermore, RV-E1 treatment
has shown similar results comparing with traditional cor-
ticosteroids treatment in herpes simplex virus-mediated
model of stromal keratitis [37].
In a mouse DES model, topical administration of RV-E1
has increased tear flow, promoted a healthy epithelium
and decreased Cyclooxygenase-2 (COX2) expression and
macrophage infiltration [19]. A unique feature of RVs is
the added protection of host tissue by up-regulating pro-
survival and down-regulating death pathways [19]. This
effect is a major therapeutic goal in many inflammatory
pathologies, including DES, since the barrier integrity of
the tissue is damaged. These studies support the assump-
tion that stimulating resolution pathways, such as RVs
[15], could have a significant role in treating chronic
inflammatory disorders, including DES.
A recent mice model of DES have shown that the
treatment of RV-E1 reduces the corneal staining by
80% and the goblet density by 20% comparing to
untreated controls, two major pathological expres-
sions of DES [20]. Moreover, a study of DES in a
mice model has shown treatment with RV-E1 may
increase tear production by 60% and induce migra-
tion of superficial corneal epithelial cells to the dry
areas [19].RV-D1 has various effects on different organs as well,
though apparently more effects are yet to be discovered.
A recent study on acute lung injury in mice model
showed reduced neutrophil infiltration and decreased
production of TNF-α and IL-6 when treated with RV-D1
[38]. These effects were similar to those of RV-E1 [38].
A different study has demonstrated RV-D1 increases in-
sulin sensitivity in adipose tissue [39]. A study of colitis
in a mice model has shown RVs from the D-series can
reduce production of pro-inflammatory cytokines such
as TNF-α and IL-1β, similarly to the effects RV-E1 dem-
onstrates in colitis [40]. Both E-series and D-series have
shown a dramatic reduction of inflammatory pain in
mice models, implying they have similar qualities [41].
Studies of ocular pathologies have focused mainly on
RV-E1. Therefore, this line of treatment is more ad-
vanced. Recently, phase-II trials have been initiated for
topical RV-E1 in patients with symptoms of DES [15].
Early results indicate symptomatic relief after a week
under RV-E1 treatment comparing to placebo, and the
relief was continued throughout the study period [15].
RV-D1 seems to have multiple sites of action, some
overlap the ones RV-E1 activates, as mentioned above.
The overlapping sites of action imply they may also have
similar mechanism of action and therefore similar effect
on several inflammatory pathologies, including inflam-
mation of the ocular surface [42,43]. However, RV-D1
differs from RV-E1 not only by their molecular origin
and molecular structures, but also by some features in
their mechanism of action. Some examples for these dif-
ferences are that RV-D1 does not activate ChemR23, a
RV-E1 receptor [42]; moreover, the receptor of RvD1
has not been identified yet [43]. RvD1 significantly de-
creased PGE2 levels in choroid-retinal endothelial cells
when stimulated with IL-1β, whereas RvE1 had little
effect on PGE2 [43] and RV-D1 has no effect on intra-
cellular Ca + 2 mobilization in neutrophils [15].
Only minor side effects from prolonged use with the
systemic intake of n-3 PUFAs were described, mainly
gastrointestinal distress [44], and no systemic side effects
were described so far with the use of Resovlins, to the
best of our knowledge.
Given that the study of RV-E1 is in advanced stages,
together with the fact that RV-D1 has similar anti-
inflammatory effects, but might also have added values
due to the differences between the two mediators, we
have decided to evaluate RV-D1 in our study.
The results of the study support previous studies
which have shown that RVs are very potent [17,45]. Tian
et al. found that RV-D1 and RV-E1 nano-molar concen-
trations treatment inhibit inflammatory signaling after
choroid-retinal endothelial cells and leukocytes were
stimulated with IL-1β [43]. The anti-inflammatory effects
of RVs are more potent by a few orders of magnitude than
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pro-inflammatory cytokines in HCE cells following the
treatment with micro-molar concentrations [13].
This study also showed that RV-D1 had inhibitory
effects on Poly I:C induction, which caused a decrease in
the I-κBα expression in HCE cells, suggesting decreased
NF-κB activity. This finding is consistent with previous
reports, which have shown the PUFA derivatives inhibit
the LPS-induced NF-κB activation and subsequent TNF-
α expression by decreased I-κBα phosphorylation and
degradation [46]. In addition, recent in-vitro studies have
shown that ALA has anti-inflammatory effects on HCE,
which is mediated through NF-κB signal transduction
[13], while n-3 PUFA inhibited NF-κB activation in an
animal model of inflammation [47].
Conclusions
Our study demonstrated several significant direct effects
of RV-D1 in reducing inflammation of the ocular surface
in-vitro. This is the first study to examine the anti-
inflammatory effects of RV-D1 at the molecular level on
a variety of cytokines which are involved in ocular sur-
face inflammation and to assess its mechanism of action.
Altogether, our in-vitro work combined with the clinical
data from studies on the systemic effects of orally admin-
istered RVs, demonstrate the significant anti-inflammatory
effects of RV-D1. Since inflammation plays a crucial role
in the pathogenesis of DES, the findings of this study have
significant therapeutic implications; RV-D1 may be used
as a potential topical anti-inflammatory treatment. More-
over, topical RV-D1 may be more beneficial than other
current anti-inflammatory agents for ocular surface in-
flammation, which are limited by their undesired long
term side effects.
Further clinical investigations are needed in order to
assess the efficacy and safety of topical RV-D1treatment
for ocular inflammation and DES in human subjects.
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